Eslicarbazepine Acetate as Therapy in Diabetic Neuropathic Pain
Status:
Terminated
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the efficacy of Eslicarbazepine acetate
(ESL) as therapy in subjects with Diabetic Neuropathic Pain (DNP) over a 15 week treatment
phase.